p53 serum antibodies as prognostic indicator in head and neck cancer

Cancer Immunology Immunotherapy

Volumn 44, Issue 2, 1997, Pages 112-116

  Werner, Jochen A ^a   Gottschlich, Stefan ^a   Folz, Benedikt J ^a   Goeroegh, Tibor ^a   Lippert, Burkard M ^a   Maass, Jan D ^a   Rudert, Heinrich ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

head and neck cancer; p53 serum antibodies; prognostic indicator

Indexed keywords

PROTEIN P53; PROTEIN P53 ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, NEOPLASM; CARCINOMA, SQUAMOUS CELL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030991572     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050363     Document Type: Article

References (34)

1. Angelopoulou K, Diamandis EP, Sutherland DJA, Kellen JA, Bunting PS (1994) Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 58:480
2. Boyle JO, Hakim J, Koch W, Riet P van der, Hruban RH, Roa RA, Carreo R, Eby YJ, Rupert JM, Sidransky D (1993) The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 53:4477
3. Bradford CR, Zhu S, Wolf GT, Poore J, Fisher SG, Beals T, McClatchey KD, Carey TE (1995) Overexpression of p53 predicts organ preservation using induction chemotherapy and radiation in patients with advanced laryngeal cancer. Otolaryngol Head Neck Surg 113:408
4. Coles C, Condie A, Chetty U, Steel CM, Evans HJ, Prosser J (1992) p53 mutations in breast cancer. Cancer Res 52:5291
5. Cooper JS, Pajak TF, Rubin P, Tupchong L, Brady LW, Leibel SA, Laramare GE, Marcial VA, Davis LW, Cox JD (1989) Second malignancies in patients who have head and neck cancers: incidence, effect of survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys 17:449
6. Crawford LV, Pim DC, Bullbrook RD (1982) Detection of antibodies against the cellular protein p53 in sera of patients with breast cancer. Int J Cancer 30:403
7. Davidoff AM, Iglehart JD, Marks JR (1992) Immune response to p53 is dependent upon p53/HSP70 complexes. Proc Natl Acad Sci USA 89:3439
8. Field JK, Spandidos DA, Malliri A, Gosney JR, Yiaguinis M, Stell PM (1991) Elevated p53 expression correlates with a history of heavy smoking in squamous cell carcinoma of the head and neck. Br J Cancer 64:573
9. Gapany M, Pavelic ZP, Gapany SR, Pavelic L, Li YG, Craven JM, Jones H, Biddinger P, Stambrook PJ, Gluckman JL (1993) Relationship between immunohistochemically detectable p53 protein and prognostic factors in head and neck tumors. Cancer Detect Prev 17:379
10. Gluckman JL, Stambrook PJ, Pavelic ZP (1994) Prognostic significance of p53 protein accumulation in early stage T1 oral cavity cancer. Eur J Cancer B Oral Oncol 30B:281
11. Gottschlich S, Maass JD, Goeroegh T, Lippen BM, Werner JA (1996) Die Immununtwort gegen p53 bei Patienten mit Plattenepithelkarzinomen der oberen Luft- und Speisewege ist unabhängig von der p53-Punktmutation. Laryngol Rhinol Otol 75:301
12. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253:49
13. Homann N, Andl T, Nees M, Schuhmann H, Herold-Mende C, Bosch FX (1993) Die Bedeutung von aberrantem p53-Protein in Kopf-Hals-Tumoren und sein Einfluß auf Proliteration und Differenzierung. HNO 41:254
14. Houbiers JGA, Burg SH van der, Van de Watering LMG, Tollenaar RA, Brand A, Felde CJ, van de, Melief CJ (1995) Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Cancer 72:637
15. Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh W, Plunkett BS, Vogelstein B, Fornace AJ (1992) A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587
16. Labrecque AJ, Naor N, Thomson G, Matlashewski G (1993) Analysis of the anti-p53 antibody response in cancer patients. Cancer Res 53:3468
17. Lane DP (1992) p53, guardian of the genome. Nature 358:15
18. Levine AJ (1990) The p53 protein and its interaction with the oncogene products of the small DNA tumor viruses. Virology 177:419
19. Linzer DIH, Levine AJ (1979) Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40 transformed cells and uninfected embryonal carcinoma cells. Cell 17:43
20. Lowe SW, Ruley HE, Jacks T, Housman DE (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957
21. Lubin R, Schlichtholz B, Bengoufa D, Zalcman G, Tredaniel J, Hirsch A, Fromentel CC de, Preudhomme C, Fenaux P, Fournier G, Mangin P, Laurent-Puig P, Pelletier G, Schlumberger M, Desgrandchamps F, LeDuc A., Peyrat JP, Janin N, Bressac B, Soussi T (1992) Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res 53:5872
22. Maass JD, Gottschlich S, Lippert BM, Niemann AM, Goeroegh T, Werner JA (1996) Antikörperbildung gegen das zelluläre Protein p53 bei Patienten mit Plattenepithelkarzinomen der oberen Luft- und Speisewege. Laryngol Rhinol Otol 75:53
23. Maass JD, Gottschlich S, Goeroegh T, Bruhn T, Lippert BM, Paulsen JI, Werner JA (1997) High rate of p53 overexpression in head and neck carcinomas detected with a refined ELISA. Anticancer Res (in press)
24. Marxsen J, Schmiegel W, Roeder C, Harder R, Juhl H, Henne-Bruns D, Kremer B, Kalthoff H (1994) Detection of the p53-antibody response in malignant and benign pancreatic disease. Br J Cancer 70:1031
25. Momand J, Zambetti GP, Olson DC, George D, Levine AJ (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237
26. Peyrat JP, Bonneterre J, Lubin R, Vanlemmens L, Fournier J, Soussi T (1995) Prognostic significance of circulating p53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet 345:621
27. Schlichtholz B, Legros Y, Gillet D, Guillard C, Marty M, Lane D, Calvo F, Soussi T (1992) The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 52:6380
28. Shin DM, Kim J, Ro JY, Hittelman J, Roth JA, Hong WK, Hittelman WN (1994) Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 54:321
29. Shin DM, Lee JS, Lippman SM, Lee JJ, Tu ZN, Choi G, Heyne K, Shin HJC, Ro JY, Goepfert H, Hong WK, Hittelman, WN (1996) p53 expression: predicting recurrence and secondary primary tumors in head and neck squamous cell carcinoma. J Natl Cancer Inst 88:519
30. Thorlacius S, Thorgilsson B, Bjoernsson J, Tryggvadottir L, Boerresen AL, Oegmundsdottir HM, Eyfjoerd L (1995) TP53mutations and abnormal p53 protein staining in breast carcinomas related to prognosis. Eur J Cancer 31A:1856
31. Vikram B (1984) Changing patterns of failure in advanced head and neck cancer. Arch Otolaryngol 110:564
32. Warnakulasuriya KA, Johnson NW (1992) Expression of p53 mutant nuclear phosphoprotein in oral carcinoma and potentially malignant oral lesions. J Oral Pathol Med 21:404
33. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP (1992) Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 52:4168
34. Wu X, Bayle JH, Olson D, Levine AJ (1993) The p53 mdm-2 autoregulalory feedback loop. Genes Dev 7:1126